Scholars Central

Conference abstractPublished 7 Mar 2016

Pharmaceutical & drug delivery technologies for efficient pain management

Authors: Abeer Al-Ghananeem

Sullivan University College of Pharmacy, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Breakthrough pain in cancer patients is a transitory exacerbation of pain experienced for a short period of time by the patient who has relatively stable and adequately controlled baseline pain. Transmucosal drug delivery through intranasal, sublingual, and buccal mucosa are considered an attractive routes to deliver breakthrough pain management medications. It avoids the hepatic first-pass clearance, which results in enhanced bioavailability and faster onset of drug action. The in-vivo pharmacokinetics of three breakthrough pain drugs has been evaluated in rabbis. Conscious rabbits were used, because anesthesia could impair the nasal mucociliary clearance and thereby allowing the formulations to remain in contact with the nasal mucosa for a longer time than would be normally expected without anesthesia. The same apply for the sublingual delivery to mimic the transient time in clinical use. In two separate experiments, the sublingual administration of Fentanyl and Oxycodone showed promising kinetic profiles, resulting in a rapid absorption with acceptable absolute bioavailability up to 82%. Factors such as formulation viscosity and drug moieties of salt versus free base were also evaluated in light of its effect on absolute bioavailability. Furthermore, Tetrahydrocannabenol (THC) intranasal delivery, also showed acceptable bioavailability comparable to the currently marketed soft gelatin capsules formulations, but irritation to nasal mucous membranes requires further drug formulation efforts to overcome this problem. With the increase demand on enhancing the quality of cancer patients’ life, transmucosal delivery offers compelling opportunities to bring new safe and effective drugs to the market.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Abeer Al-Ghananeem”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels